<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30206090</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>9</Issue><PubDate><Year>2018</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Study protocol for the MEXiletine hydrochloride administration trial: a placebo-controlled, randomised, double-blind, multicentre, crossover study of its efficacy and safety in spinal and bulbar muscular atrophy (MEXPRESS).</ArticleTitle><Pagination><StartPage>e023041</StartPage><MedlinePgn>e023041</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e023041</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2018-023041</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Spinal and bulbar muscular atrophy (SBMA) is a slowly progressive neuromuscular disease. Cold exposure often leads to worsening of motor symptoms including paresis. Although mexiletine hydrochloride administration has been shown to be effective for the treatment of several muscular diseases, its effectiveness in SBMA has not been validated to date. The trial will test it as a symptomatic drug for cold paresis. This study is the first trial to evaluate the efficacy and safety of mexiletine hydrochloride administration in patients with SBMA.</AbstractText><AbstractText Label="METHODS AND ANALYSIS">A placebo-controlled, randomised, double-blind, multicentre, crossover clinical trial will be conducted to assess the safety and efficacy of mexiletine hydrochloride in patients with SBMA. The eligible patients will be assigned randomly in a 1:1 ratio to two groups in a double-blind manner. Participants will take mexiletine hydrochloride (300&#x2009;mg/day) or a placebo orally three times a day for 4 weeks (period 1). After a 1-week washout period, participants will take the other drug for 4 weeks (period 2). The primary endpoint is the difference in distal latencies between room temperature and cold exposure conditions.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">This study will be conducted in compliance with the Helsinki Declaration and the Ethical Guidelines for Medical and Health Research Involving Human Subjects by the Japanese government and has been approved by the ethics committee of Nagoya University Graduate School of Medicine, as a central institutional review board, and by each facility. The results will be disseminated in peer-reviewed journals and at scientific conferences.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER">UMIN000026150; Pre-results.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Shinichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashizume</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hijikata</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2646-5271</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inagaki</LastName><ForeName>Tomonori</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-6272-5953</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinoshita</LastName><ForeName>Fumie</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Biostatistics Section, Centre for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakatochi</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biostatistics Section, Centre for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Yumiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Biostatistics Section, Centre for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirakawa</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Tomohiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Masahisa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9453-9311</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>UMIN-CTR</DataBankName><AccessionNumberList><AccessionNumber>UMIN000026150</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061567">Voltage-Gated Sodium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>1U511HHV4Z</RegistryNumber><NameOfSubstance UI="D008801">Mexiletine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="Y">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003080" MajorTopicYN="N">Cold Temperature</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008801" MajorTopicYN="Y">Mexiletine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009460" MajorTopicYN="N">Neurologic Examination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010291" MajorTopicYN="Y">Paresis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061567" MajorTopicYN="N">Voltage-Gated Sodium Channel Blockers</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cold paresis</Keyword><Keyword MajorTopicYN="N">mexiletine hydrochloride</Keyword><Keyword MajorTopicYN="N">myotonia-like muscle contraction</Keyword><Keyword MajorTopicYN="N">neuromuscular disease</Keyword><Keyword MajorTopicYN="N">randomised controlled trial</Keyword><Keyword MajorTopicYN="N">spinal and bulbar muscular atrophy</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30206090</ArticleId><ArticleId IdType="pmc">PMC6144396</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2018-023041</ArticleId><ArticleId IdType="pii">bmjopen-2018-023041</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 1968;18:671&#x2013;80. 10.1212/WNL.18.7.671</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.18.7.671</ArticleId><ArticleId IdType="pubmed">4233749</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Tanaka F, Adachi H, et al. . Pathogenesis and therapy of Spinal and Bulbar Muscular Atrophy (SBMA). Prog Neurobiol 2012;99:246&#x2013;56. 10.1016/j.pneurobio.2012.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2012.05.007</ArticleId><ArticleId IdType="pubmed">22609045</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorar&#xf9; G, D&#x2019;Ascenzo C, Polo A, et al. . Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. J Neurol Sci 2008;264:100&#x2013;5. 10.1016/j.jns.2007.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2007.08.012</ArticleId><ArticleId IdType="pubmed">17854832</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Wilson EM, Lubahn DB, et al. . Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991;352:77&#x2013;9. 10.1038/352077a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/352077a0</ArticleId><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Dadgar N, Albertelli M, et al. . Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J Clin Invest 2006;116:2663&#x2013;72. 10.1172/JCI28773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI28773</ArticleId><ArticleId IdType="pmc">PMC1564432</ArticleId><ArticleId IdType="pubmed">16981011</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki K, Nakanishi H, Nakamura T, et al. . Myotonia-like symptoms in a patient with spinal and bulbar muscular atrophy. Neuromuscul Disord 2015;25:913&#x2013;5. 10.1016/j.nmd.2015.08.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2015.08.006</ArticleId><ArticleId IdType="pubmed">26363965</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi JR, Bundy B, Statland J, et al. . Non-dystrophic myotonia: prospective study of objective and patient reported outcomes. Brain 2013;136:2189&#x2013;200. 10.1093/brain/awt133</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt133</ArticleId><ArticleId IdType="pmc">PMC3692030</ArticleId><ArticleId IdType="pubmed">23771340</ArticleId></ArticleIdList></Reference><Reference><Citation>Straver DC, van Asseldonk JT, Notermans NC, et al. . Cold paresis in multifocal motor neuropathy. J Neurol 2011;258:212&#x2013;7. 10.1007/s00415-010-5712-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-010-5712-3</ArticleId><ArticleId IdType="pmc">PMC3036831</ArticleId><ArticleId IdType="pubmed">20803025</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulos PT, Heiman-Patterson TD, Alexander GM, et al. . Patch clamp studies of the thr1313met mutant sodium channel causing paramyotonia congenita. Muscle Nerve 2000;23:1736&#x2013;47. 10.1002/1097-4598(200011)23:11&lt;1736::AID-MUS10&gt;3.0.CO;2-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-4598(200011)23:11&lt;1736::AID-MUS10&gt;3.0.CO;2-1</ArticleId><ArticleId IdType="pubmed">11054753</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiura Y, Makita N, Li L, et al. . Cold induces shifts of voltage dependence in mutant SCN4A, causing hypokalemic periodic paralysis. Neurology 2003;61:914&#x2013;8. 10.1212/01.WNL.0000086820.54065.A0</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000086820.54065.A0</ArticleId><ArticleId IdType="pubmed">14557559</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodgkin AL, Katz B. The effect of temperature on the electrical activity of the giant axon of the squid. J Physiol 1949;109:240&#x2013;9. 10.1113/jphysiol.1949.sp004388</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.1949.sp004388</ArticleId><ArticleId IdType="pmc">PMC1392577</ArticleId><ArticleId IdType="pubmed">15394322</ArticleId></ArticleIdList></Reference><Reference><Citation>Dlouh&#xe1; H, Donselaar Y, Teisinger J, et al. . Effect of temperature and ouabain on th Na+--K+ activated membrane ATPase and electrogenic ionic pump of the golden hamster and mouse diaphragm. Physiol Bohemoslov 1980;29:543&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">6259677</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove SB. Effects of temperature on neuromuscular electrophysiology. Muscle Nerve 2001;24:867&#x2013;82. 10.1002/mus.1084</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.1084</ArticleId><ArticleId IdType="pubmed">11410914</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb J, Cannon SC. Cold-induced defects of sodium channel gating in atypical periodic paralysis plus myotonia. Neurology 2008;70:755&#x2013;61. 10.1212/01.wnl.0000265397.70057.d8</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000265397.70057.d8</ArticleId><ArticleId IdType="pmc">PMC4094148</ArticleId><ArticleId IdType="pubmed">17898326</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon SC. Channelopathies of skeletal muscle excitability. Compr Physiol 2015;5:761&#x2013;90. 10.1002/cphy.c140062</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cphy.c140062</ArticleId><ArticleId IdType="pmc">PMC4754081</ArticleId><ArticleId IdType="pubmed">25880512</ArticleId></ArticleIdList></Reference><Reference><Citation>Statland JM, Bundy BN, Wang Y, et al. . Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA 2012;308:1357&#x2013;65. 10.1001/jama.2012.12607</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.12607</ArticleId><ArticleId IdType="pmc">PMC3564227</ArticleId><ArticleId IdType="pubmed">23032552</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai K, Kuwabara S, Arai K, et al. . Muscle cramp in Machado-Joseph disease: altered motor axonal excitability properties and mexiletine treatment. Brain 2003;126:965&#x2013;73. 10.1093/brain/awg073</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awg073</ArticleId><ArticleId IdType="pubmed">12615652</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan AW, Tetzlaff JM, Altman DG, et al. . SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200&#x2013;7. 10.7326/0003-4819-158-3-201302050-00583</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-158-3-201302050-00583</ArticleId><ArticleId IdType="pmc">PMC5114123</ArticleId><ArticleId IdType="pubmed">23295957</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan AW, Tetzlaff JM, G&#xf8;tzsche PC, et al. . SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586 10.1136/bmj.e7586</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.e7586</ArticleId><ArticleId IdType="pmc">PMC3541470</ArticleId><ArticleId IdType="pubmed">23303884</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz KF, Altman DG, Moher D, et al. . CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010;152:726&#x2013;32. 10.7326/0003-4819-152-11-201006010-00232</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-152-11-201006010-00232</ArticleId><ArticleId IdType="pubmed">20335313</ArticleId></ArticleIdList></Reference><Reference><Citation>Streib EW, Sun SF, Yarkowsky T. Transient paresis in myotonic syndromes: a simplified electrophysiologic approach. Muscle Nerve 1982;5:719&#x2013;23. 10.1002/mus.880050909</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.880050909</ArticleId></ArticleIdList></Reference><Reference><Citation>Streib EW. AAEE minimonograph #27: differential diagnosis of myotonic syndromes. Muscle Nerve 1987;10:603&#x2013;15. 10.1002/mus.880100704</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.880100704</ArticleId><ArticleId IdType="pubmed">3309651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuntzer T, Michel P. Muscle membrane polarisation after provocative tests, and after cooling: the normal CMAP changes to be expected. Clin Neurophysiol 2004;115:1457&#x2013;63. 10.1016/j.clinph.2004.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2004.01.004</ArticleId><ArticleId IdType="pubmed">15134715</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier E, Viala K, Gervais H, et al. . Cold extends electromyography distinction between ion channel mutations causing myotonia. Ann Neurol 2006;60:356&#x2013;65. 10.1002/ana.20905</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20905</ArticleId><ArticleId IdType="pubmed">16786525</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel P, Sternberg D, Jeannet PY, et al. . Comparative efficacy of repetitive nerve stimulation, exercise, and cold in differentiating myotonic disorders. Muscle Nerve 2007;36:643&#x2013;50. 10.1002/mus.20856</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20856</ArticleId><ArticleId IdType="pubmed">17654559</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono K, Ebara S, Fuji T, et al. . Myelopathy hand. New clinical signs of cervical cord damage. J Bone Joint Surg Br 1987;69:215&#x2013;9. 10.1302/0301-620X.69B2.3818752</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.69B2.3818752</ArticleId><ArticleId IdType="pubmed">3818752</ArticleId></ArticleIdList></Reference><Reference><Citation>Mano T, Katsuno M, Banno H, et al. . Tongue pressure as a novel biomarker of spinal and bulbar muscular atrophy. Neurology 2014;82:255&#x2013;62. 10.1212/WNL.0000000000000041</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000041</ArticleId><ArticleId IdType="pubmed">24353334</ArticleId></ArticleIdList></Reference><Reference><Citation>Barohn RJ, McIntire D, Herbelin L, et al. . Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 1998;841:769&#x2013;72. 10.1111/j.1749-6632.1998.tb11015.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1998.tb11015.x</ArticleId><ArticleId IdType="pubmed">9668327</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmann JR, Andres P, Mendoza M, et al. . Guidelines for the use and performance of quantitative outcome measures in ALS clinical trials. J Neurol Sci 1997;147:97&#x2013;111. 10.1016/S0022-510X(96)05220-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(96)05220-3</ArticleId><ArticleId IdType="pubmed">9094067</ArticleId></ArticleIdList></Reference><Reference><Citation>The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II study group. Arch Neurol 1996;53:141&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8639063</ArticleId></ArticleIdList></Reference><Reference><Citation>Banno H, Katsuno M, Suzuki K, et al. . Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 2009;65:140&#x2013;50. 10.1002/ana.21540</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21540</ArticleId><ArticleId IdType="pubmed">19259967</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Banno H, Suzuki K, et al. . Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:875&#x2013;84. 10.1016/S1474-4422(10)70182-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70182-4</ArticleId><ArticleId IdType="pubmed">20691641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Suzuki K, et al. . A functional scale for spinal and bulbar muscular atrophy: cross-sectional and longitudinal study. Neuromuscul Disord 2015;25:554&#x2013;62. 10.1016/j.nmd.2015.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2015.03.008</ArticleId><ArticleId IdType="pmc">PMC5608513</ArticleId><ArticleId IdType="pubmed">25913211</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih R, Wang Z, Heo M, et al. . Lower limb skeletal muscle mass: development of dual-energy X-ray absorptiometry prediction model. J Appl Physiol 2000;89:1380&#x2013;6. 10.1152/jappl.2000.89.4.1380</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jappl.2000.89.4.1380</ArticleId><ArticleId IdType="pubmed">11007572</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridge P, Pocock NA, Nguyen T, et al. . Prediction of appendicular skeletal and fat mass in children: excellent concordance of dual-energy X-ray absorptiometry and magnetic resonance imaging. J Pediatr Endocrinol Metab 2009;22:795&#x2013;804. 10.1515/JPEM.2009.22.9.795</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/JPEM.2009.22.9.795</ArticleId><ArticleId IdType="pubmed">19960889</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Wang Z, Zhang J, et al. . Estimation of total body skeletal muscle mass in Chinese adults: prediction model by dual-energy X-ray absorptiometry. PLoS One 2013;8:e53561 10.1371/journal.pone.0053561</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0053561</ArticleId><ArticleId IdType="pmc">PMC3538629</ArticleId><ArticleId IdType="pubmed">23308254</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuhara S, Bito S, Green J, et al. . Translation, adaptation, and validation of the SF-36 health survey for use in Japan. J Clin Epidemiol 1998;51:1037&#x2013;44. 10.1016/S0895-4356(98)00095-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0895-4356(98)00095-X</ArticleId><ArticleId IdType="pubmed">9817121</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent KA, Carr AJ, Walburn J, et al. . Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology 2007;68:1051&#x2013;7. 10.1212/01.wnl.0000257819.47628.41</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000257819.47628.41</ArticleId><ArticleId IdType="pubmed">17389311</ArticleId></ArticleIdList></Reference><Reference><Citation>Statland JM, Wang Y, Richesson R, et al. . An interactive voice response diary for patients with non-dystrophic myotonia. Muscle Nerve 2011;44:30&#x2013;5. 10.1002/mus.22007</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22007</ArticleId><ArticleId IdType="pmc">PMC3233757</ArticleId><ArticleId IdType="pubmed">21674518</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada S, Hashizume A, Hijikata Y, et al. . Decreased peak expiratory flow associated with muscle fiber-type switching in spinal and bulbar muscular atrophy. PLoS One 2016;11:e0168846 10.1371/journal.pone.0168846</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0168846</ArticleId><ArticleId IdType="pmc">PMC5179045</ArticleId><ArticleId IdType="pubmed">28005993</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Banno H, et al. . Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain 2012;135:2838&#x2013;48. 10.1093/brain/aws170</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws170</ArticleId><ArticleId IdType="pubmed">22773541</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijikata Y, Katsuno M, Suzuki K, et al. . Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy. Ann Clin Transl Neurol 2016;3:537&#x2013;46. 10.1002/acn3.324</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.324</ArticleId><ArticleId IdType="pmc">PMC4931718</ArticleId><ArticleId IdType="pubmed">27386502</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>